TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Fundamental Analysis

NYSE:TEVA • US8816242098

33.98 USD
+0.06 (+0.18%)
At close: Feb 13, 2026
33.91 USD
-0.07 (-0.21%)
After Hours: 2/13/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

TEVA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. TEVA has an excellent profitability rating, but there are concerns on its financial health. TEVA scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • TEVA had positive earnings in the past year.
  • TEVA had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: TEVA reported negative net income in multiple years.
  • In the past 5 years TEVA always reported a positive cash flow from operatings.
TEVA Yearly Net Income VS EBIT VS OCF VS FCFTEVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5B -10B -15B

1.2 Ratios

  • With an excellent Return On Assets value of 3.46%, TEVA belongs to the best of the industry, outperforming 83.25% of the companies in the same industry.
  • The Return On Equity of TEVA (17.81%) is better than 89.53% of its industry peers.
  • TEVA's Return On Invested Capital of 9.93% is amongst the best of the industry. TEVA outperforms 89.53% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for TEVA is below the industry average of 12.64%.
  • The last Return On Invested Capital (9.93%) for TEVA is above the 3 year average (9.79%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.46%
ROE 17.81%
ROIC 9.93%
ROA(3y)-0.66%
ROA(5y)-1.34%
ROE(3y)-6.71%
ROE(5y)-9.48%
ROIC(3y)9.79%
ROIC(5y)8.89%
TEVA Yearly ROA, ROE, ROICTEVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • TEVA's Profit Margin of 8.16% is amongst the best of the industry. TEVA outperforms 83.25% of its industry peers.
  • TEVA has a Operating Margin of 19.87%. This is amongst the best in the industry. TEVA outperforms 87.43% of its industry peers.
  • TEVA's Operating Margin has been stable in the last couple of years.
  • Looking at the Gross Margin, with a value of 52.89%, TEVA is in the better half of the industry, outperforming 65.44% of the companies in the same industry.
  • TEVA's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 19.87%
PM (TTM) 8.16%
GM 52.89%
OM growth 3Y-2.92%
OM growth 5Y0.54%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.99%
GM growth 5Y2.49%
TEVA Yearly Profit, Operating, Gross MarginsTEVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), TEVA is creating some value.
  • The number of shares outstanding for TEVA has been increased compared to 1 year ago.
  • Compared to 5 years ago, TEVA has more shares outstanding
  • Compared to 1 year ago, TEVA has an improved debt to assets ratio.
TEVA Yearly Shares OutstandingTEVA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
TEVA Yearly Total Debt VS Total AssetsTEVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B

2.2 Solvency

  • TEVA has a debt to FCF ratio of 14.64. This is a negative value and a sign of low solvency as TEVA would need 14.64 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 14.64, TEVA is in the better half of the industry, outperforming 76.96% of the companies in the same industry.
  • A Debt/Equity ratio of 1.89 is on the high side and indicates that TEVA has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 1.89, TEVA is doing worse than 78.01% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.89
Debt/FCF 14.64
Altman-Z N/A
ROIC/WACC1.2
WACC8.3%
TEVA Yearly LT Debt VS Equity VS FCFTEVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.3 Liquidity

  • A Current Ratio of 1.04 indicates that TEVA should not have too much problems paying its short term obligations.
  • TEVA's Current ratio of 1.04 is on the low side compared to the rest of the industry. TEVA is outperformed by 84.29% of its industry peers.
  • TEVA has a Quick Ratio of 1.04. This is a bad value and indicates that TEVA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • TEVA has a worse Quick ratio (0.80) than 81.68% of its industry peers.
Industry RankSector Rank
Current Ratio 1.04
Quick Ratio 0.8
TEVA Yearly Current Assets VS Current LiabilitesTEVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 17.27% over the past year.
  • The Earnings Per Share has been growing slightly by 4.89% on average over the past years.
  • The Revenue has been growing slightly by 4.32% in the past year.
  • The Revenue has been growing slightly by 0.71% on average over the past years.
EPS 1Y (TTM)17.27%
EPS 3Y4.89%
EPS 5YN/A
EPS Q2Q%35.21%
Revenue 1Y (TTM)4.32%
Revenue growth 3Y4.96%
Revenue growth 5Y0.71%
Sales Q2Q%11.4%

3.2 Future

  • TEVA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.67% yearly.
  • The Revenue is expected to grow by 1.00% on average over the next years.
EPS Next Y-4.58%
EPS Next 2Y3.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0.34%
Revenue Next 2Y1%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TEVA Yearly Revenue VS EstimatesTEVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5B 10B 15B 20B
TEVA Yearly EPS VS EstimatesTEVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 11.36, which indicates a very decent valuation of TEVA.
  • 89.01% of the companies in the same industry are more expensive than TEVA, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 27.97. TEVA is valued rather cheaply when compared to this.
  • The Price/Forward Earnings ratio is 11.93, which indicates a very decent valuation of TEVA.
  • Based on the Price/Forward Earnings ratio, TEVA is valued cheaply inside the industry as 86.39% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.96, TEVA is valued rather cheaply.
Industry RankSector Rank
PE 11.36
Fwd PE 11.93
TEVA Price Earnings VS Forward Price EarningsTEVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, TEVA is valued cheaply inside the industry as 85.34% of the companies are valued more expensively.
  • TEVA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. TEVA is cheaper than 81.68% of the companies in the same industry.
Industry RankSector Rank
P/FCF 33.95
EV/EBITDA 11.77
TEVA Per share dataTEVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 15

4.3 Compensation for Growth

  • TEVA has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.67%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • TEVA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TEVA PHARMACEUTICAL-SP ADR

NYSE:TEVA (2/13/2026, 8:04:00 PM)

After market: 33.91 -0.07 (-0.21%)

33.98

+0.06 (+0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-28
Earnings (Next)05-05
Inst Owners14.54%
Inst Owner Change0.81%
Ins Owners0.42%
Ins Owner Change-1.67%
Market Cap38.98B
Revenue(TTM)17.26B
Net Income(TTM)1.41B
Analysts82.86
Price Target0.11 (-99.68%)
Short Float %2.94%
Short Ratio3.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.53%
Min EPS beat(2)16.51%
Max EPS beat(2)38.54%
EPS beat(4)4
Avg EPS beat(4)16.39%
Min EPS beat(4)4.65%
Max EPS beat(4)38.54%
EPS beat(8)7
Avg EPS beat(8)8.31%
EPS beat(12)9
Avg EPS beat(12)5.55%
EPS beat(16)10
Avg EPS beat(16)3.14%
Revenue beat(2)2
Avg Revenue beat(2)3.32%
Min Revenue beat(2)0.9%
Max Revenue beat(2)5.75%
Revenue beat(4)2
Avg Revenue beat(4)-0.7%
Min Revenue beat(4)-4.77%
Max Revenue beat(4)5.75%
Revenue beat(8)5
Avg Revenue beat(8)0.11%
Revenue beat(12)8
Avg Revenue beat(12)1.11%
Revenue beat(16)8
Avg Revenue beat(16)-0.59%
PT rev (1m)4.75%
PT rev (3m)98.2%
EPS NQ rev (1m)-7.96%
EPS NQ rev (3m)-4.24%
EPS NY rev (1m)1.21%
EPS NY rev (3m)2.6%
Revenue NQ rev (1m)-3.61%
Revenue NQ rev (3m)-2.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.1%
Valuation
Industry RankSector Rank
PE 11.36
Fwd PE 11.93
P/S 2.26
P/FCF 33.95
P/OCF 23.64
P/B 4.93
P/tB N/A
EV/EBITDA 11.77
EPS(TTM)2.99
EY8.8%
EPS(NY)2.85
Fwd EY8.38%
FCF(TTM)1
FCFY2.95%
OCF(TTM)1.44
OCFY4.23%
SpS15.04
BVpS6.9
TBVpS-10.35
PEG (NY)N/A
PEG (5Y)N/A
Graham Number21.54
Profitability
Industry RankSector Rank
ROA 3.46%
ROE 17.81%
ROCE 12.57%
ROIC 9.93%
ROICexc 11.42%
ROICexgc 68.51%
OM 19.87%
PM (TTM) 8.16%
GM 52.89%
FCFM 6.65%
ROA(3y)-0.66%
ROA(5y)-1.34%
ROE(3y)-6.71%
ROE(5y)-9.48%
ROIC(3y)9.79%
ROIC(5y)8.89%
ROICexc(3y)11.13%
ROICexc(5y)9.93%
ROICexgc(3y)65.11%
ROICexgc(5y)55.38%
ROCE(3y)12.4%
ROCE(5y)11.26%
ROICexgc growth 3Y16.18%
ROICexgc growth 5Y11.01%
ROICexc growth 3Y9.88%
ROICexc growth 5Y9.93%
OM growth 3Y-2.92%
OM growth 5Y0.54%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.99%
GM growth 5Y2.49%
F-Score8
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 1.89
Debt/FCF 14.64
Debt/EBITDA 3.38
Cap/Depr 50%
Cap/Sales 2.9%
Interest Coverage 250
Cash Conversion 37.21%
Profit Quality 81.48%
Current Ratio 1.04
Quick Ratio 0.8
Altman-Z N/A
F-Score8
WACC8.3%
ROIC/WACC1.2
Cap/Depr(3y)47.55%
Cap/Depr(5y)45.36%
Cap/Sales(3y)3.08%
Cap/Sales(5y)3.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.27%
EPS 3Y4.89%
EPS 5YN/A
EPS Q2Q%35.21%
EPS Next Y-4.58%
EPS Next 2Y3.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.32%
Revenue growth 3Y4.96%
Revenue growth 5Y0.71%
Sales Q2Q%11.4%
Revenue Next Year0.34%
Revenue Next 2Y1%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.19%
EBIT growth 3Y1.9%
EBIT growth 5Y1.25%
EBIT Next Year18.84%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y53.27%
FCF growth 3Y3.28%
FCF growth 5Y12.47%
OCF growth 1Y32.24%
OCF growth 3Y1.22%
OCF growth 5Y6.28%

TEVA PHARMACEUTICAL-SP ADR / TEVA FAQ

What is the fundamental rating for TEVA stock?

ChartMill assigns a fundamental rating of 4 / 10 to TEVA.


What is the valuation status of TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?

ChartMill assigns a valuation rating of 7 / 10 to TEVA PHARMACEUTICAL-SP ADR (TEVA). This can be considered as Undervalued.


Can you provide the profitability details for TEVA PHARMACEUTICAL-SP ADR?

TEVA PHARMACEUTICAL-SP ADR (TEVA) has a profitability rating of 7 / 10.


What is the valuation of TEVA PHARMACEUTICAL-SP ADR based on its PE and PB ratios?

The Price/Earnings (PE) ratio for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 11.36 and the Price/Book (PB) ratio is 4.93.


What is the earnings growth outlook for TEVA PHARMACEUTICAL-SP ADR?

The Earnings per Share (EPS) of TEVA PHARMACEUTICAL-SP ADR (TEVA) is expected to decline by -4.58% in the next year.